Inhibition of the synthesis of beta-app or of the activity of the a-beta peptide in the choroid plexus

Abstract

The invention relates to the treatment of neurodegenerative diseases, in particular Alzheimer's disease, by inhibition of the synthesis of βAPP or of the activity of the Aβ peptide in the choroid plexus.

1 - 9 . (canceled) 
     
     
         10 . A method of decreasing the synthesis of βAPP in the choroid plexus of a patient affected with Alzheimer's disease, comprising administering an expression vector coding for an inhibitor of the βAPP protein to said patient targeting the choroid plexuses of said patient, said inhibitor being selected from antisense oligonucleotides and interfering RNAs directed against the gene coding of said βAPP protein. 
     
     
         11 . The method of  claim 10 , wherein said vector is derived from an adeno-associated virus. 
     
     
         12 . The method of  claim 10 , wherein said antisense oligonucleotide or interfering RNA is directed against a region of the mRNA coding for the C-terminal portion of the endogenous βAPP protein in order not to interfere with the synthesis of a soluble functional recombinant form of the βAPP protein encoded by nucleic acids 201-2213 of SEQ ID NO:3. 
     
     
         13 . The method of  claim 10 , wherein said method reduces the Aβ peptide synthesis. 
     
     
         14 . The method according to  claim 10 , wherein the vector is derived from an adeno-associated virus of serotype 2, 4, or 5. 
     
     
         15 . The method according to  claim 10 , wherein said Alzheimer's disease is a sporadic or family form of Alzheimer's disease. 
     
     
         16 . The method according to  claim 10 , wherein said vector is administered by injection into the retro-orbital sinus. 
     
     
         17 . The method according to  claim 10 , wherein said vector is administered by injection into the venous system. 
     
     
         18 . The method according to  claim 10 , wherein said vector is combined with a soluble functional recombinant form of the βAPP protein, wherein the antisense oligonucleotide or interfering RNA is directed against a region of the mRNA coding for the C-terminal portion of the endogenous βAPP protein in order not to interfere with the synthesis of the soluble functional recombinant form of the βAPP protein encoded by nucleic acids 201-2213 of SEQ ID NO:3. 
     
     
         19 . The method of  claim 18 , wherein said soluble recombinant βAPP protein is overexpressed through a viral vector.